© Brighton Collaboration 2023. All rights reserved.
Menu
Brighton Collaboration develops standardized templates for benefit-risk assessments of new vaccine candidates.
(1 - 5 of 5)
“A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine” is now available. This paper[...]
The Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO; ex-V3SWG) Working Group has developed a standardized template to describe the key considerations for the[...]
Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration’s Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as part of the Safety[...]
The COVID-19 pandemic has devastated the world as we know it. Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines[...]
Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030
© Brighton Collaboration 2023. All rights reserved.